NASDAQ: GOSS · Life Sciences · 6 alerts · CIK 1728117
Share price
$10.98Close, Nov 16
Market cap
$67.2M
Shares outstanding
6.12MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Gossamer Bio, Inc. filings on SEC EDGAR ↗
Gossamer Bio reported Q3 2026 financial results, highlighting the submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH. The company also noted a structured private placement that provided $25 million upfront and could unlock an additional $125 million upon FDA acceptance of the NDA. Additionally, the company completed a 1-for-80 reverse stock split in September 2026 to regain Nasdaq compliance.
Term
Q3 2026
“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH. Furthermore, FDA acceptance of the application in 2026 would, subject to other customary closing conditions, unlock up to approximately $125 million in additional committed capital to support our priorities, including preparations for a potential launch. We remain focused on supporting the FDA’s review and preparing for a potential commercial launch of seralutinib in 2027.”
Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer
Gossamer Bio reported total revenue of $64.6 million for the nine months ended September 30, 2026, compared to $34.7 million in the prior year, primarily driven by collaboration contracts. Despite the revenue growth, the company recorded a net loss of $77.8 million for the period, impacted by significant non-cash items including a $54.9 million remeasurement of warrant liability and a $43.8 million gain on debt extinguishment.
Gossamer Bio stockholders approved the potential issuance of common stock exceeding 20% of outstanding shares in connection with a Securities Purchase Agreement dated August 20, 2026. The approval covers shares issuable upon the exercise of Pre-Funded Warrants, FDA Approval Warrants, and the conversion of Series A-1, A-2, and A-3 Preferred Stock, satisfying Nasdaq Listing Rules 5635(c) and 5635(d).
Gossamer Bio has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, resolving a deficiency notice originally received on April 8, 2026. The company achieved compliance following a 1-for-80 reverse stock split that became effective on September 10, 2026, and the matter is now closed.
Gossamer Bio has submitted its first New Drug Application (NDA) to the FDA for seralutinib for the treatment of pulmonary arterial hypertension (PAH). The submission is supported by data from the Phase 3 PROSERA and Phase 2 TORREY studies, following a Pre-NDA meeting with the regulator in June 2026. The FDA is expected to determine whether to accept the application for filing later this year.